Menstrual Cramps Treatment Market by Type (Primary Dysmenorrhea and Secondary Dysmenorrhea), Treatment (Non-steroidal Anti-inflammatory Drugs and Hormonal Therapy), Distribution Channel (Hospital Pharmacies, Drug stores and Retail Pharmacies ad Online Providers) and Geography (North America, Europe, APAC and RoW) - Forecast up to 2027
Menstrual cramps are pains which cause in lower abdomen and in the back. This is also known as dysmenorrhea. The pain can remain for 2 to 3 days. Chemicals known as prostaglandins are produced by the body which is responsible for most of the symptoms connected with menstrual discomfort. People with more amounts of prostaglandin may experience highly severe uterine contractions and pain. Dysmenorrhea is categorized on the basis of type which includes primary dysmenorrhea and secondary dysmenorrhea. Surge in demand for menstrual cramps treatment because of the increase in cases of menstrual cramps propel the menstrual cramps treatment market growth. Apart from this, the rise in government support for healthcare infrastructure developments further fuel the growth of the market. Apart from this, the minimum price of over-the-counter medicines such as ibuprofen leads to growth in demand for menstrual cramps drugs and further accelerates the menstrual cramps treatment market growth. However, the less demand for menstrual cramps treatment in under development nations may impede the market growth. The Menstrual Cramps Treatment Market is projected to grow at a rate of 4.0% CAGR by 2027.
Menstrual Cramps Treatment Market by Type
Primary Dysmenorrhea
Secondary Dysmenorrhea
Menstrual Cramps Treatment Market by Treatment
Non-steroidal Anti-inflammatory Drugs
Hormonal Therapy
Menstrual Cramps Treatment Market by Distribution Channel
Hospital Pharmacies
Drug stores and Retail Pharmacies
Online Providers
Menstrual Cramps Treatment Market by Geography
North America
Europe
Asia Pacific
Rest of the World
The types are bifurcate into Primary Dysmenorrhea and Secondary Dysmenorrhea. The Primary Dysmenorrhea segment is obtaining significant popularity in the market by capturing a highest share in the menstrual cramps treatment market. The reason which propels the segment growth is the surge in occurrence of high menstrual bleeding among women and changes in lifestyle, which results in primary dysmenorrhea.
Further on the basis of treatment, the market segmented into Non-steroidal Anti-inflammatory Drugs and Hormonal Therapy. The Non-steroidal Anti-inflammatory Drugs segment held the largest share in the menstrual cramps treatment market. The largest share of the segment is attributed to the benefits of Non-steroidal Anti-inflammatory Drugs. The benefits include low cost, high availability in pharmacy and drug stores, and high therapeutic effect due to which most of the women use Non-steroidal Anti-inflammatory Drugs.
Further, in the market for Distribution Channel is divided into Hospital Pharmacies, Drug stores and Retail Pharmacies ad Online Providers. Among which the drugs stores and retail pharmacies segment held a significant share in the menstrual cramps treatment market. This is can be accredited to the huge sales of medicines from drug stores and retail pharmacies and a surge in patients looking treatment for menstrual cramps.
Geographically, the menstrual cramps treatment market is classified into North America, Europe, Asia Pacific and rest of the world. Among them the North America region has captured the maximum share in the market. Owing to the existence of leading vendors in the region, increase in government initiatives as well as well developed healthcare infrastructure in the region the market is growing highly in the region.
Furthermore, the changing lifestyle of people around the world is projected to influence the global market dynamic during the forecast period. Changing lifestyles along with the unhealthy food habits have significant impact on the human body. This further leads to increasing prevalence of dysmenorrhea/ menstrual cramps among women. In addition, the environmental changes are also considered a contributing factor which increases the risk of menstrual cramps.
AbbVie Inc., Torrent Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Johnson and Johnson, Bayer AG, Taj Pharmaceuticals Limited, Abbott Laboratories, Pfizer Inc., and GlaxoSmithKline plc, are some of the competitors that are dominating the menstrual cramps treatment market.
Therefore, the women around the world have become more conscious about the menstrual cramps than past now-a-days and the problems regarding the dysmenorrhea are increasing as well. Since, women are seeking for pain relief where menstrual cramps treatments are highly available in the market.
To examine and analyze the menstrual cramps treatment market size by key regions, type treatment and distribution channel.
To understand the structure of menstrual cramps treatment market by recognizing its various sub segments.
Emphasizes on the key global menstrual cramps treatment competitors, to define, describe and analyze the market competition landscape, market share, value, SWOT analysis and development plans in next few years.
To analyze the menstrual cramps treatment market in terms of individual growth trends, future prospects and their contribution to the whole market.
Menstrual Cramps Treatment Market by Type
Primary Dysmenorrhea
Secondary Dysmenorrhea
Menstrual Cramps Treatment Market by Treatment
Non-steroidal Anti-inflammatory Drugs
Hormonal Therapy
Menstrual Cramps Treatment Market by Distribution Channel
Hospital Pharmacies
Drug stores and Retail Pharmacies
Online Providers
Menstrual Cramps Treatment Market by Geography
North America
Europe
Asia Pacific
Rest of the World
The types are bifurcate into Primary Dysmenorrhea and Secondary Dysmenorrhea. The Primary Dysmenorrhea segment is obtaining significant popularity in the market by capturing a highest share in the menstrual cramps treatment market. The reason which propels the segment growth is the surge in occurrence of high menstrual bleeding among women and changes in lifestyle, which results in primary dysmenorrhea.
Further on the basis of treatment, the market segmented into Non-steroidal Anti-inflammatory Drugs and Hormonal Therapy. The Non-steroidal Anti-inflammatory Drugs segment held the largest share in the menstrual cramps treatment market. The largest share of the segment is attributed to the benefits of Non-steroidal Anti-inflammatory Drugs. The benefits include low cost, high availability in pharmacy and drug stores, and high therapeutic effect due to which most of the women use Non-steroidal Anti-inflammatory Drugs.
Further, in the market for Distribution Channel is divided into Hospital Pharmacies, Drug stores and Retail Pharmacies ad Online Providers. Among which the drugs stores and retail pharmacies segment held a significant share in the menstrual cramps treatment market. This is can be accredited to the huge sales of medicines from drug stores and retail pharmacies and a surge in patients looking treatment for menstrual cramps.
Geographically, the menstrual cramps treatment market is classified into North America, Europe, Asia Pacific and rest of the world. Among them the North America region has captured the maximum share in the market. Owing to the existence of leading vendors in the region, increase in government initiatives as well as well developed healthcare infrastructure in the region the market is growing highly in the region.
Furthermore, the changing lifestyle of people around the world is projected to influence the global market dynamic during the forecast period. Changing lifestyles along with the unhealthy food habits have significant impact on the human body. This further leads to increasing prevalence of dysmenorrhea/ menstrual cramps among women. In addition, the environmental changes are also considered a contributing factor which increases the risk of menstrual cramps.
AbbVie Inc., Torrent Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Johnson and Johnson, Bayer AG, Taj Pharmaceuticals Limited, Abbott Laboratories, Pfizer Inc., and GlaxoSmithKline plc, are some of the competitors that are dominating the menstrual cramps treatment market.
Therefore, the women around the world have become more conscious about the menstrual cramps than past now-a-days and the problems regarding the dysmenorrhea are increasing as well. Since, women are seeking for pain relief where menstrual cramps treatments are highly available in the market.
To examine and analyze the menstrual cramps treatment market size by key regions, type treatment and distribution channel.
To understand the structure of menstrual cramps treatment market by recognizing its various sub segments.
Emphasizes on the key global menstrual cramps treatment competitors, to define, describe and analyze the market competition landscape, market share, value, SWOT analysis and development plans in next few years.
To analyze the menstrual cramps treatment market in terms of individual growth trends, future prospects and their contribution to the whole market.
1. EXECUTIVE SUMMARY
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. TYPE: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Primary Dysmenorrhea
5.3. Secondary Dysmenorrhea
6. TREATMENT: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Non-steroidal Anti-inflammatory Drugs
6.3. Hormonal Therapy
7. DISTRIBUTION CHANNEL: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. Hospital pharmacies
7.3. Drug store and retail pharmacies
7.4. Online providers
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. AbbVie Inc.
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. Torrent Pharmaceuticals Ltd.
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. Sun Pharmaceutical Industries Ltd.
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. Dr. Reddy's Laboratories Ltd.
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Johnson and Johnson
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. Bayer AG
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. Taj Pharmaceuticals Limited
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. Abbott Laboratories
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. Pfizer Inc.
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. GlaxoSmithKline plc
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. TYPE: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Primary Dysmenorrhea
5.3. Secondary Dysmenorrhea
6. TREATMENT: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Non-steroidal Anti-inflammatory Drugs
6.3. Hormonal Therapy
7. DISTRIBUTION CHANNEL: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. Hospital pharmacies
7.3. Drug store and retail pharmacies
7.4. Online providers
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. AbbVie Inc.
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. Torrent Pharmaceuticals Ltd.
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. Sun Pharmaceutical Industries Ltd.
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. Dr. Reddy's Laboratories Ltd.
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Johnson and Johnson
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. Bayer AG
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. Taj Pharmaceuticals Limited
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. Abbott Laboratories
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. Pfizer Inc.
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. GlaxoSmithKline plc
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
LIST OF TABLES
TABLE 1. GLOBAL MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL MENSTRUAL CRAMPS TREATMENT MARKET VALUE FOR PRIMARY DYSMENORRHEA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL MENSTRUAL CRAMPS TREATMENT MARKET VALUE FOR SECONDARY DYSMENORRHEA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL MENSTRUAL CRAMPS TREATMENT MARKET VALUE FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL MENSTRUAL CRAMPS TREATMENT MARKET VALUE FOR HORMONAL THERAPY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL MENSTRUAL CRAMPS TREATMENT MARKET VALUE FOR HOSPITAL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL MENSTRUAL CRAMPS TREATMENT MARKET VALUE FOR DRUG STORE AND RETAIL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL MENSTRUAL CRAMPS TREATMENT MARKET VALUE FOR ONLINE PROVIDERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 12. NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 13. NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 14. NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 15. U.S MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 16. U.S MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 17. U.S MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 18. CANADA MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 19. CANADA MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 20. CANADA MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 21. EUROPE MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 22. EUROPE MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 23. EUROPE MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 24. EUROPE MENSTRUAL CRAMPS TREATMENT MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 25. GERMANY MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 26. GERMANY MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 27. GERMANY MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 28. U.K MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 29. U.K MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 30. U.K MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 31. FRANCE MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 32. FRANCE MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 33. FRANCE MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 34. ITALY MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 35. ITALY MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 36. ITALY MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 37. SPAIN MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 38. SPAIN MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 39. SPAIN MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 40. ROE MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 41. ROE MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 42. ROE MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 43. ASIA PACIFC MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 44. ASIA PACIFC MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 45. ASIA PACIFC MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 46. ASIA PACIFC MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 47. CHINA MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 48. CHINA MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 49. CHINA MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 50. INDIA MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 51. INDIA MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 52. INDIA MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 53. JAPAN MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 54. JAPAN MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 55. JAPAN MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 56. REST OF APAC MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 57. REST OF APAC MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 58. REST OF APAC MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 59. REST OF WORLD MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 60. REST OF WORLD MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 61. REST OF WORLD MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 62. ABBVIE INC.: FINANCIALS
TABLE 63. ABBVIE INC.: PRODUCTS & SERVICES
TABLE 64. ABBVIE INC.: RECENT DEVELOPMENTS
TABLE 65. TORRENT PHARMACEUTICALS LTD.: FINANCIALS
TABLE 66. TORRENT PHARMACEUTICALS LTD.: PRODUCTS & SERVICES
TABLE 67. TORRENT PHARMACEUTICALS LTD.: RECENT DEVELOPMENTS
TABLE 68. SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIALS
TABLE 69. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS & SERVICES
TABLE 70. SUN PHARMACEUTICAL INDUSTRIES LTD.: RECENT DEVELOPMENTS
TABLE 71. DR. REDDY'S LABORATORIES LTD.: FINANCIALS
TABLE 72. DR. REDDY'S LABORATORIES LTD.: PRODUCTS & SERVICES
TABLE 73. DR. REDDY'S LABORATORIES LTD.: RECENT DEVELOPMENTS
TABLE 74. JOHNSON AND JOHNSON: FINANCIALS
TABLE 75. JOHNSON AND JOHNSON: PRODUCTS & SERVICES
TABLE 76. JOHNSON AND JOHNSON: RECENT DEVELOPMENTS
TABLE 77. BAYER AG: FINANCIALS
TABLE 78. BAYER AG: PRODUCTS & SERVICES
TABLE 79. BAYER AG: RECENT DEVELOPMENTS
TABLE 80. TAJ PHARMACEUTICALS LIMITED: FINANCIALS
TABLE 81. TAJ PHARMACEUTICALS LIMITED: PRODUCTS & SERVICES
TABLE 82. TAJ PHARMACEUTICALS LIMITED: RECENT DEVELOPMENTS
TABLE 83. ABBOTT LABORATORIES: FINANCIALS
TABLE 84. ABBOTT LABORATORIES: PRODUCTS & SERVICES
TABLE 85. ABBOTT LABORATORIES: RECENT DEVELOPMENTS
TABLE 86. PFIZER INC.: FINANCIALS
TABLE 87. PFIZER INC.: PRODUCTS & SERVICES
TABLE 88. PFIZER INC.: RECENT DEVELOPMENTS
TABLE 89. GLAXOSMITHKLINE PLC: FINANCIALS
TABLE 90. GLAXOSMITHKLINE PLC: PRODUCTS & SERVICES
TABLE 91. GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
TABLE 1. GLOBAL MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL MENSTRUAL CRAMPS TREATMENT MARKET VALUE FOR PRIMARY DYSMENORRHEA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL MENSTRUAL CRAMPS TREATMENT MARKET VALUE FOR SECONDARY DYSMENORRHEA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL MENSTRUAL CRAMPS TREATMENT MARKET VALUE FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL MENSTRUAL CRAMPS TREATMENT MARKET VALUE FOR HORMONAL THERAPY, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL MENSTRUAL CRAMPS TREATMENT MARKET VALUE FOR HOSPITAL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL MENSTRUAL CRAMPS TREATMENT MARKET VALUE FOR DRUG STORE AND RETAIL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL MENSTRUAL CRAMPS TREATMENT MARKET VALUE FOR ONLINE PROVIDERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 12. NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 13. NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 14. NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 15. U.S MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 16. U.S MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 17. U.S MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 18. CANADA MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 19. CANADA MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 20. CANADA MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 21. EUROPE MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 22. EUROPE MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 23. EUROPE MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 24. EUROPE MENSTRUAL CRAMPS TREATMENT MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 25. GERMANY MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 26. GERMANY MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 27. GERMANY MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 28. U.K MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 29. U.K MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 30. U.K MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 31. FRANCE MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 32. FRANCE MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 33. FRANCE MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 34. ITALY MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 35. ITALY MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 36. ITALY MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 37. SPAIN MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 38. SPAIN MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 39. SPAIN MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 40. ROE MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 41. ROE MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 42. ROE MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 43. ASIA PACIFC MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 44. ASIA PACIFC MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 45. ASIA PACIFC MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 46. ASIA PACIFC MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 47. CHINA MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 48. CHINA MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 49. CHINA MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 50. INDIA MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 51. INDIA MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 52. INDIA MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 53. JAPAN MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 54. JAPAN MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 55. JAPAN MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 56. REST OF APAC MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 57. REST OF APAC MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 58. REST OF APAC MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 59. REST OF WORLD MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 60. REST OF WORLD MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY TREATMENT, 2021-2027 (USD BILLION)
TABLE 61. REST OF WORLD MENSTRUAL CRAMPS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 62. ABBVIE INC.: FINANCIALS
TABLE 63. ABBVIE INC.: PRODUCTS & SERVICES
TABLE 64. ABBVIE INC.: RECENT DEVELOPMENTS
TABLE 65. TORRENT PHARMACEUTICALS LTD.: FINANCIALS
TABLE 66. TORRENT PHARMACEUTICALS LTD.: PRODUCTS & SERVICES
TABLE 67. TORRENT PHARMACEUTICALS LTD.: RECENT DEVELOPMENTS
TABLE 68. SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIALS
TABLE 69. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS & SERVICES
TABLE 70. SUN PHARMACEUTICAL INDUSTRIES LTD.: RECENT DEVELOPMENTS
TABLE 71. DR. REDDY'S LABORATORIES LTD.: FINANCIALS
TABLE 72. DR. REDDY'S LABORATORIES LTD.: PRODUCTS & SERVICES
TABLE 73. DR. REDDY'S LABORATORIES LTD.: RECENT DEVELOPMENTS
TABLE 74. JOHNSON AND JOHNSON: FINANCIALS
TABLE 75. JOHNSON AND JOHNSON: PRODUCTS & SERVICES
TABLE 76. JOHNSON AND JOHNSON: RECENT DEVELOPMENTS
TABLE 77. BAYER AG: FINANCIALS
TABLE 78. BAYER AG: PRODUCTS & SERVICES
TABLE 79. BAYER AG: RECENT DEVELOPMENTS
TABLE 80. TAJ PHARMACEUTICALS LIMITED: FINANCIALS
TABLE 81. TAJ PHARMACEUTICALS LIMITED: PRODUCTS & SERVICES
TABLE 82. TAJ PHARMACEUTICALS LIMITED: RECENT DEVELOPMENTS
TABLE 83. ABBOTT LABORATORIES: FINANCIALS
TABLE 84. ABBOTT LABORATORIES: PRODUCTS & SERVICES
TABLE 85. ABBOTT LABORATORIES: RECENT DEVELOPMENTS
TABLE 86. PFIZER INC.: FINANCIALS
TABLE 87. PFIZER INC.: PRODUCTS & SERVICES
TABLE 88. PFIZER INC.: RECENT DEVELOPMENTS
TABLE 89. GLAXOSMITHKLINE PLC: FINANCIALS
TABLE 90. GLAXOSMITHKLINE PLC: PRODUCTS & SERVICES
TABLE 91. GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
